Dr Lal Path Labs has plans to invest in expanding its laboratory chain from the current eight labs to 30 labs by 2005. The company, which has its presence only in the capital, plans to expand its network in east and south.
Each lab is expected to envisage an investment of Rs.3-5 crore. The company is planning to fund the expansion by inducting a strategic partner and through internal accruals.
Presently, the company is doing clinical
research for companies such as Pfizer, Novartis, Ranbaxy and Wockhardt.
It may be added that the Path Labs offers
over 1,400 different investigations and panels in the discipline of molecular
diagnostics, biophysics, virology, flow cytometry and critical tests of LDL
subfraction and neo-natal tests.
